Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector

Lancet

Volumn 364, Issue 9452, 2004, Pages 2181-2187

  Gaspar, H Bobby ^a,b   Parsley, Kathryn L ^a   Howe, Steven ^a   King, Doug ^a   Gilmour, Kimberly C ^a,b   Sinclair, Joanna ^a   Brouns, Gaby ^a   Schmidt, Manfred ^c   Kalle, Christof Von ^c,d   Barington, Torben ^e   Jakobsen, Marianne A ^e   Christensen, Hans O ^e   Ghonaium, Abdulaziz Al ^f   White, Harry N ^a   Smith, John L ^g   Levinsky, Prof Roland J ^a   Ali, Prof Robin R ^a,h   Kinnon, Prof Christine ^a   Thrasher, Prof Adrian J ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c UNIVERSITY OF FREIBURG   (Germany)

^d CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^g SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE RECEPTOR; CYTOKINE RECEPTOR GAMMA CHAIN; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ARTICLE; CASE REPORT; CHILD; CLINICAL FEATURE; COMMON VARIABLE IMMUNODEFICIENCY; DISEASE SEVERITY; EXPRESSION VECTOR; GAMMA RETROVIRUS VECTOR; GIBBON LEUKEMIA VIRUS; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOGLOBULIN GENE; IMMUNOSTIMULATION; PATIENT MONITORING; PRIORITY JOURNAL; SAMPLE SIZE; SIDE EFFECT; SOMATIC GENE THERAPY; SOMATIC MUTATION; T LYMPHOCYTE ACTIVATION;

EID: 19944421384     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)17590-9     Document Type: Article

References (19)

1. Fischer A, Cavazzana-Calvo M, de Saint BG, et al. Naturally occurring primary deficiencies of the immune system. Annu Rev Immunol. 15:1997;93-124
2. Noguchi M, Yi H, Rosenblatt HM, et al. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell. 73:1993;147-157
3. White H, Thrasher A, Veys P, Kinnon C, Gaspar HB. Intrinsic defects of B cell function in X-linked severe combined immunodeficiency. Eur J Immunol. 30:2000;732-737
4. Buckley RH, Schiff SE, Schiff RI, et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med. 340:1999;508-516
5. Antoine C, Muller S, Cant A, et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet. 361:2003;553-560
6. Haddad E, Landais P, Friedrich W, et al. Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients. Blood. 91:1998;3646-3653
7. Whitwam T, Haskins ME, Henthorn PS, et al. Retroviral marking of canine bone marrow: long-term, high-level expression of human interleukin-2 receptor common gamma chain in canine lymphocytes. Blood. 92:1998;1565-1575
8. Stephan V, Wahn V, Le Deist F, et al. Atypical X-linked severe combined immunodeficiency due to possible spontaneous reversion of the genetic defect in T cells. N Engl J Med. 335:1996;1563-1567
9. Schmidt M, Glimm H, Lemke N, et al. A model for the detection of clonality in marked hematopoietic stem cells. Ann NY Acad Sci. 938:2001;146-155
10. Teshima T, Ferrara JL. Understanding the alloresponse: new approaches to graft-versus-host disease prevention. Semin Hematol. 39:2002;15-22
11. Hess AD, Thoburn CJ. Immunobiology and immunotherapeutic implications of syngeneic/autologous graft-versus-host disease. Immunol Rev. 157:1997;111-123
12. Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med. 346:2002;1185-1193
13. Hollander GA, Wang B, Nichogiannopoulou A, et al. Developmental control point in induction of thymic cortex regulated by a subpopulation of prothymocytes. Nature. 373:1995;350-353
14. van Ewijk W, Hollander G, Terhorst C, Wang B. Stepwise development of thymic microenvironments in vivo is regulated by thymocyte subsets. Development. 127:2000;1583-1591
15. Klug DB, Carter C, Gimenez-Conti IB, Richie ER. Cutting edge: thymocyte-independent and thymocyte-dependent phases of epithelial patterning in the fetal thymus. J Immunol. 169:2002;2842-2845
16. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 348:2003;255-256
17. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 302:2003;415-419
18. Patel DD, Gooding ME, Parrott RE, Curtis KM, Haynes BF, Buckley RH. Thymic function after hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med. 342:2000;1325-1332
19. Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 296:2002;2410-2413